Every Form 4 that Soligenix, Inc. (SNGX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow SNGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SNGX filings page.
SOLIGENIX, INC. (SNGX) reported that director Jerome B. Zeldis received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share, expire on June 16, 2036, and vest in four equal installments from December 17, 2026 through September 17, 2027. No Rule 10b5-1 trading plan is reported for this grant.
SOLIGENIX, INC. (SNGX) reported that director Robert J. Rubin received a grant of 78,947 stock options on September 17, 2026. The options have an exercise price of $0.38 per share, expire on September 16, 2036, and vest ratably on four dates through September 17, 2027.
SOLIGENIX, INC. (SNGX) reported that director Diane L. Parks received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share, expire on September 16, 2036, and vest ratably on four dates through September 17, 2027.
SOLIGENIX, INC. (SNGX) reported that director Anthony Gregg Lapointe received a grant of stock options covering 78,947 shares of common stock on September 17, 2026. The options have an exercise price of $0.38 per share and expire on September 16, 2036.
The option grant vests ratably on December 17, 2026, March 17, 2027, June 17, 2027, and September 17, 2027. All 78,947 option shares are held directly following this grant, and no Rule 10b5-1 trading plan is reported.
Soligenix consulting chief medical officer Richard Straube reported an equity award in the form of stock options. On December 11, 2025, he received options to acquire 10,000 shares of Soligenix common stock at an exercise price of $1.63 per share, expiring on December 10, 2035.
According to the filing, the option vested immediately as to 25% of the shares, with the remaining 75% vesting in 12 installments (or nearly equal installments) on each three‑month anniversary of December 11, 2025. The filing shows 10,000 derivative securities beneficially owned directly following this transaction.
Soligenix, Inc. reported an insider equity award to its chief scientific officer. On December 11, 2025, the officer received a stock option covering 100,000 shares of Soligenix common stock at an exercise price of $1.63 per share.
The option expires on December 10, 2035. According to the disclosure, 25% of the option vested immediately on December 11, 2025, and the remaining 75% will vest in 12 approximately equal installments on each three-month anniversary of that date.
Soligenix, Inc. reported an insider equity award to its Chief Financial Officer, Jonathan L. Guarino. He received a stock option grant covering 100,000 options to purchase common stock at an exercise price of $ 1.63 per share on December 11, 2025.
The option expires on December 10, 2035. It vested immediately as to 25% of the shares, with the remaining 75% scheduled to vest in 12 equal installments on each three month anniversary of December 11, 2025. Following this grant, he beneficially owns 100,000 derivative securities directly.
Soligenix, Inc. reported that its Chairman, CEO and President Christopher J. Schaber received a stock option grant covering 200,000 shares of common stock on December 11, 2025, with an exercise price of $1.63 per share and an expiration date of December 10, 2035. The option vests 25% immediately, with the remaining 75% vesting in 12 equal installments on each three-month anniversary of December 11, 2025.